tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

FNCH Stock Latest News

Finch Therapeutics Faces Nasdaq Delisting and Patent Litigation
Company AnnouncementsFinch Therapeutics Faces Nasdaq Delisting and Patent Litigation
2M ago
8K
FNCH
Finch Therapeutics trading resumes
PremiumThe Fly
Finch Therapeutics trading resumes
10M ago
FNCH
Finch Therapeutics trading halted, volatility trading pause
PremiumThe Fly
Finch Therapeutics trading halted, volatility trading pause
10M ago
FNCH
Finch Announces Reverse Stock Split of Common Stock
PremiumPress Releases
Finch Announces Reverse Stock Split of Common Stock
11M ago
FNCH
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
PremiumPress Releases
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
12M ago
FNCH
Finch Therapeutics appoints Matthew Blischak CEO
PremiumThe FlyFinch Therapeutics appoints Matthew Blischak CEO
12M ago
FNCH
Finch enters CP101 clinical trial agreement with Brigham and Women’s Hospital
PremiumThe Fly
Finch enters CP101 clinical trial agreement with Brigham and Women’s Hospital
1y ago
FNCH
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
PremiumPress Releases
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
1y ago
FNCH
Finch Therapeutics price target lowered to $7 from $17 at H.C. Wainwright
PremiumThe Fly
Finch Therapeutics price target lowered to $7 from $17 at H.C. Wainwright
1y ago
FNCH
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
PremiumPress Releases
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
1y ago
FNCH
Oppenheimer emerging biotech analyst to hold analyst/industry conference call
PremiumThe Fly
Oppenheimer emerging biotech analyst to hold analyst/industry conference call
1y ago
FNCH
Oppenheimer emerging biotech analyst to hold analyst/industry conference call
PremiumThe Fly
Oppenheimer emerging biotech analyst to hold analyst/industry conference call
1y ago
FNCH
Oppenheimer emerging biotech analyst to hold analyst/industry conference call
PremiumThe FlyOppenheimer emerging biotech analyst to hold analyst/industry conference call
1y ago
FNCH
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
PremiumPress Releases
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
1y ago
FNCH
Finch Therapeutics to reduce workforce by 95%
PremiumThe Fly
Finch Therapeutics to reduce workforce by 95%
1y ago
FNCH
Finch Therapeutics to discontinues Phase 3 trial of CP101
PremiumThe Fly
Finch Therapeutics to discontinues Phase 3 trial of CP101
1y ago
FNCH
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
PremiumPress Releases
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
1y ago
FNCH
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
PremiumPress Releases
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
2y ago
FNCH
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
PremiumPress Releases
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
2y ago
FNCH
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
PremiumPress ReleasesFinch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
2y ago
FNCH
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
PremiumPress Releases
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
2y ago
FNCH
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
PremiumPress Releases
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
2y ago
FNCH

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >